Clinical trial, blinded, parallel group study to analyze differences in the safety of roflumilast administered once daily on alternate days for two weeks before the regular schedule once a day. [Ensayo clínico, ciego y de grupos paralelos para analizar diferencias en la seguridad de roflumilast administrado una vez al día en días alternos durante dos semanas respecto a la pauta habitual una vez al día]

Trial Profile

Clinical trial, blinded, parallel group study to analyze differences in the safety of roflumilast administered once daily on alternate days for two weeks before the regular schedule once a day. [Ensayo clínico, ciego y de grupos paralelos para analizar diferencias en la seguridad de roflumilast administrado una vez al día en días alternos durante dos semanas respecto a la pauta habitual una vez al día]

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jul 2015

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Nov 2013 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 08 May 2013 Planned end date changed from 29 Aug 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top